Website thumbnail FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes Related Blindness (1)
February 5, 2025

FDA Approves the First Anti-VEGF Port Delivery System for Diabetic Macular Edema

Got a patient with DME? Say goodbye to the monthly jab—Susvimo, the first continuous drug delivery system for DME just…

Panic,Cat,Scare,Of,Injection,Syringe,Or,Vaccine.,Risk,Of
February 7, 2022

After a Shot to the Eye: Patient-Reported “Issues” after Intravitreal Injection

Intravitreal injections (IVI) of pharmacological agents have become the gold standard for the treatment of many retinal diseases, including neovascular…

latest posts
Website thumbnail FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes Related Blindness (1)
February 5, 2025

FDA Approves the First Anti-VEGF Port Delivery System for Diabetic Macular Edema

Panic,Cat,Scare,Of,Injection,Syringe,Or,Vaccine.,Risk,Of
February 7, 2022

After a Shot to the Eye: Patient-Reported “Issues” after Intravitreal Injection
August 11, 2021

Roche’s Port Delivery nAMD System: Looking Likely?

Funny,Wrestler,With,Winners,Gold,Medal
June 4, 2021

Gene Transfer is Anti-VEGF’s Future

Happy girl on board of sailing yacht have a fun.
November 13, 2020

Beyond Anti-VEGF: Novel Therapies Show Promise in DME

3D art Holy Grail
October 20, 2020

Extended-Release Implants: Re-Vana Therapeutics’ Quest for an Anti-VEGF Grail

Businesswoman Stands On Long Road With Road Map Painted On It
September 24, 2020

Mapping the Road Ahead: Stem Cell Therapy in Diabetic Retinopathy

iStock 600416150
February 20, 2020

Going Boldly into the Suprachoroidal Space

Discover our fascinating content at issuu

explore